- Home
- GLBZ vs INTS Comparison
GLBZ vs INTS Comparison
Compare GLBZ & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLBZ
- INTS
- Stock Information
- Founded
- GLBZ 1949
- INTS 2012
- Country
- GLBZ United States
- INTS United States
- Employees
- GLBZ N/A
- INTS N/A
- Industry
- GLBZ Major Banks
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- GLBZ Finance
- INTS Health Care
- Exchange
- GLBZ Nasdaq
- INTS Nasdaq
- Market Cap
- GLBZ 13.5M
- INTS 12.2M
- IPO Year
- GLBZ N/A
- INTS 2023
- Fundamental
- Price
- GLBZ $4.69
- INTS $0.54
- Analyst Decision
- GLBZ
- INTS Strong Buy
- Analyst Count
- GLBZ 0
- INTS 4
- Target Price
- GLBZ N/A
- INTS $4.50
- AVG Volume (30 Days)
- GLBZ 6.6K
- INTS 86.0M
- Earning Date
- GLBZ 10-31-2025
- INTS 11-07-2025
- Dividend Yield
- GLBZ N/A
- INTS N/A
- EPS Growth
- GLBZ N/A
- INTS N/A
- EPS
- GLBZ 0.01
- INTS N/A
- Revenue
- GLBZ $12,771,000.00
- INTS N/A
- Revenue This Year
- GLBZ N/A
- INTS N/A
- Revenue Next Year
- GLBZ N/A
- INTS N/A
- P/E Ratio
- GLBZ $492.00
- INTS N/A
- Revenue Growth
- GLBZ 13.82
- INTS N/A
- 52 Week Low
- GLBZ $3.89
- INTS $0.19
- 52 Week High
- GLBZ $6.99
- INTS $3.40
- Technical
- Relative Strength Index (RSI)
- GLBZ 52.23
- INTS 54.50
- Support Level
- GLBZ $4.36
- INTS $0.23
- Resistance Level
- GLBZ $4.89
- INTS $1.74
- Average True Range (ATR)
- GLBZ 0.20
- INTS 0.15
- MACD
- GLBZ -0.01
- INTS 0.04
- Stochastic Oscillator
- GLBZ 62.86
- INTS 20.51
About GLBZ Glen Burnie Bancorp
Glen Burnie Bancorp is a bank holding company for The Bank of Glen Burnie. It offers retail and commercial banking services such as checking, savings, loans, mobile banking, online banking, wire transfer, ACH services, debit cards, automated teller machines, and safe deposit boxes among others. The bank generates its revenue in the form of interest income. All of the revenues are earned within the United States.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.